Meredith S. Eno

Statistics

Publications

Citations

388

H-Index

Active since

2012

Affiliations

Blueprint Medicines (United States)(Current)

Boston College

Yonsei University

Meredith S. Eno is an author at Blueprint Medicines (United States) specializing in targeted cancer therapy, tyrosine kinase inhibitors, and medicine.

ORCID

Publications per year

2012–2022

Publications

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC

Stefanie S. Schalm, Tom Dineen, Sangbin Lim et al. · Annals of Oncology · 2020 · 50 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +11

Nickel-Catalyzed Asymmetric Kumada Cross-Coupling of Symmetric Cyclic Sulfates

Meredith S. Eno, Alexander Lu, James P. Morken · Journal of the American Chemical Society · 2016 · 47 citations · Full text

Natural Sciences, Chemistry, Catalysis +4

Enantioselective Hydroformylation of 1-Alkenes with Commercial Ph-BPE Ligand

Zhiyong Yu, Meredith S. Eno, Alexandra H. Annis et al. · Organic Letters · 2015 · 37 citations

Natural Sciences, Chemistry, Catalysis +6

Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC

Chiara Conti, John Campbell, Rich Woessner et al. · Cancer Research · 2021 · 24 citations

Medicine, Oncology, Pharmacology +17

1–5 of 9